These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30311168)

  • 1. Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer.
    Kawaguchi T; Yan L; Qi Q; Peng X; Edge SB; Young J; Yao S; Liu S; Otsuji E; Takabe K
    Ann Surg Oncol; 2018 Dec; 25(13):4037-4046. PubMed ID: 30311168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
    Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
    BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.
    Marino AL; Evangelista AF; Vieira RA; Macedo T; Kerr LM; Abrahão-Machado LF; Longatto-Filho A; Silveira HC; Marques MM
    BMC Cancer; 2014 Oct; 14():739. PubMed ID: 25277099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer.
    Bao S; Hu T; Liu J; Su J; Sun J; Ming Y; Li J; Wu N; Chen H; Zhou M
    J Nanobiotechnology; 2021 Jan; 19(1):22. PubMed ID: 33436002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.
    Li Z; Peng Z; Gu S; Zheng J; Feng D; Qin Q; He J
    Anticancer Res; 2017 Aug; 37(8):4455-4468. PubMed ID: 28739740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA).
    Kim SY; Kawaguchi T; Yan L; Young J; Qi Q; Takabe K
    Ann Surg Oncol; 2017 Oct; 24(10):2943-2949. PubMed ID: 28766230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
    Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
    Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Cellular Levels of MicroRNA-9 and MicroRNA-221 Correlate with Cancer Stemness and Predict Poor Outcome in Human Breast Cancer.
    Cheng CW; Yu JC; Hsieh YH; Liao WL; Shieh JC; Yao CC; Lee HJ; Chen PM; Wu PE; Shen CY
    Cell Physiol Biochem; 2018; 48(5):2205-2218. PubMed ID: 30110679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data.
    Zhang Z; Pan B; Lv S; Ji Z; Wu Q; Lang R; He Q; Zhao X
    Cell Physiol Biochem; 2018; 49(2):678-695. PubMed ID: 30165365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expression of miR-34a Associated with Less Aggressive Cancer Biology but Not with Survival in Breast Cancer.
    Tokumaru Y; Katsuta E; Oshi M; Sporn JC; Yan L; Le L; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
    BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.
    Sharma P; Saraya A; Sharma R
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e289-e301. PubMed ID: 29380534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
    Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
    Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer.
    Volinia S; Croce CM
    Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7413-7. PubMed ID: 23589849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
    Lánczky A; Nagy Á; Bottai G; Munkácsy G; Szabó A; Santarpia L; Győrffy B
    Breast Cancer Res Treat; 2016 Dec; 160(3):439-446. PubMed ID: 27744485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.
    Wu YS; Lin H; Chen D; Yi Z; Zeng B; Jiang Y; Ren G
    Gene; 2019 May; 697():86-93. PubMed ID: 30779946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.